Glenmark Cleared By FDA to Market Generic Pravachol
Posted on: Wednesday, 16 May 2007, 09:00 CDT
Mumbai-based Glenmark Pharmaceuticals has received FDA approval to market pravastatin sodium tablets 10mg, 20mg and 40mg, a generic version of Bristol-Myers Squibb's statin Pravachol.
Pravachol, a cholesterol-lowering drug, has annual sales of over $861 million, according to Glenmark. The generics company said that it is manufacturing the formulation in its facility in Goa, India.
Last month, Glenmark also received US FDA approval to market naproxen sodium tablets, a generic version of Roche's brand Anaprox and naproxen tablets, a generic version of Roche's brand Naprosyn.
Source: Datamonitor
Related Articles
- Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
- Mylan's Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
- Sun Pharma Wins FDA Approval for Generic Sinemet CR Tablets
- FDA Approves Generic AIDS Drug
- FDA Approves Glenmark's Generic Nausea Tablets
- The World's Leading Pharmaceutical Companies Face Difficult Times Due to the Generics Erosion
- Jordanian Firm Plans Pounds 500m London Float
- Prasco Ships Glimepiride Tablets, the Authorized Generic of Amaryl(R)
- Sanofi-Aventis Acts to Stop Planned Generic of Allegra; Woodcliff Lake's Barr Will Oppose Injunction
- Sanofi-Aventis Acts to Stop Planned Generic of Allegra
Rating: 2.8 / 5 (5 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds